New Basal Insulins: a Clinical Perspective of Their Use in the Treatment of Type 2 Diabetes and Novel Treatment Options Beyond Basal Insulin

2017 ◽  
Vol 17 (10) ◽  
Author(s):  
Patrick F. Frias ◽  
Juan Pablo Frias
Keyword(s):  
Type 2 Diabetes ◽  
Basal Insulin ◽  
Treatment Options ◽  
Clinical Perspective ◽  
Novel Treatment

scholarly journals The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes

2018 ◽  
Vol 9 (5) ◽  
pp. 151-155 ◽  
Author(s):  
Taylor R. Inman ◽  
Erika Plyushko ◽  
Nicholas P. Austin ◽  
Jeremy L. Johnson
Keyword(s):  
Type 2 Diabetes ◽  
Weight Loss ◽  
Basal Insulin ◽  
Patient Adherence ◽  
Treatment Options ◽  
New Combination ◽  
Once Daily ◽  
Glucagon Like Peptide 1 ◽  
New Treatment

The prevalence of type 2 diabetes necessitates the development of new treatment options to individualize therapy. Basal insulin has been a standard treatment option for years, while glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have grown in use over the past decade due to glucose-lowering efficacy and weight loss potential. There are two new combination injectable products that have recently been approved combining basal insulins with GLP-1 RAs in single pen-injector devices. United States guidelines recently emphasize the option to use combination injectable therapy with GLP-1 RAs and basal insulin once the basal insulin has been optimally titrated as a second- or third-line agent in addition to metformin without reaching the goal A1c. Insulin glargine/lixisenatide 100/33 (IGlarLixi) can be dosed between 15 and 60 units once daily from a single pen-injector device. Insulin degludec/liraglutide 100/3.6 (IDegLira) can be dosed between 10 and 50 units once daily, also from a single pen-injector device. Maximum doses, while measured in units, correspond to limits defined by each individual GLP-1 RA. The dual use of basal insulin plus GLP-1 RA is non-inferior compared with basal insulin plus a single injection of prandial insulin at the largest meal and compared with twice daily-dosed premixed insulins; and this combination is associated with weight loss and less hypoglycemia. These new combination products could help providers effectively and efficiently follow clinical practice guidelines while enhancing patient adherence with injectable medications.

Reasons for different patterns of basal insulin persistence after initiation among people with type 2 diabetes (T2D)

2017 ◽  
Vol 12 (S 01) ◽  
pp. S1-S84
Author(s):  
M Peyrot ◽  
J Ivanova ◽  
C Zao ◽  
L Schmerold ◽  
S King ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Basal Insulin

Exenatide: a novel treatment of Type 2 diabetes

Therapy ◽  
2005 ◽  
Vol 2 (2) ◽  
pp. 207-222 ◽  
Author(s):  
Bo Ahren
Keyword(s):  
Type 2 Diabetes ◽  
Novel Treatment

Switching to Insulin Glargine 300 U/mL (Gla-300) Improves Glycemic Control and Reduces Nocturnal Hypoglycemia in Patients (Pts) with Type 2 Diabetes (T2DM) on Basal Insulin Supported Oral Therapy (BOT)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1020-P ◽  
Author(s):  
JOCHEN SEUFERT ◽  
ANDREAS FRITSCHE ◽  
HELMUT ANDERTEN ◽  
KATRIN PEGELOW ◽  
STEFAN PSCHERER ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Glargine ◽  
Basal Insulin ◽  
Oral Therapy ◽  
Nocturnal Hypoglycemia

952-P: Improving Glycemic Management of Patients with Type 2 Diabetes in Acute Geriatric Care by Using a Basal Insulin Algorithm Incorporated into a Workflow and Decision Support System

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 952-P
Author(s):  
ANGELA LIBISELLER ◽  
KATHARINA M. LICHTENEGGER ◽  
JULIA KOPANZ ◽  
ANTONELLA DE CAMPO ◽  
TATJANA WIESINGER ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Decision Support ◽  
Decision Support System ◽  
Support System ◽  
Basal Insulin ◽  
Geriatric Care ◽  
Glycemic Management ◽  
Acute Geriatric Care
Sign in / Sign up

Export Citation Format

Share Document